7CC Stock Overview
A clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Check-Cap Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.73 |
| 52 Week High | US$2.98 |
| 52 Week Low | US$0.68 |
| Beta | 0.18 |
| 11 Month Change | -31.78% |
| 3 Month Change | -54.37% |
| 1 Year Change | -75.17% |
| 33 Year Change | -94.93% |
| 5 Year Change | -97.01% |
| Change since IPO | -99.94% |
Recent News & Updates
Recent updates
Shareholder Returns
| 7CC | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 7.4% | 2.8% | 1.1% |
| 1Y | -75.2% | -5.7% | 7.2% |
Return vs Industry: 7CC underperformed the German Medical Equipment industry which returned -4.7% over the past year.
Return vs Market: 7CC underperformed the German Market which returned 8.6% over the past year.
Price Volatility
| 7CC volatility | |
|---|---|
| 7CC Average Weekly Movement | 11.1% |
| Medical Equipment Industry Average Movement | 6.2% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 7CC's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 7CC's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 85 | n/a | www.check-cap.com |
Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient’s back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation. The company was incorporated in 2004 and is based in Isfiya, Israel.
Check-Cap Ltd. Fundamentals Summary
| 7CC fundamental statistics | |
|---|---|
| Market cap | €4.47m |
| Earnings (TTM) | -€16.63m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.3x
P/E RatioIs 7CC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 7CC income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$17.57m |
| Earnings | -US$17.57m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.00 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 7CC perform over the long term?
See historical performance and comparison